---
title: "Tirzepatide"
description: "Tirzepatide is a dual GIP/GLP-1 receptor agonist used for type 2 diabetes and obesity in India under prescription."
canonical: "https://www.kesho.health/glossary/tirzepatide"
markdown_url: "https://www.kesho.health/md/glossary/tirzepatide"
language: "en-IN"
---

# Tirzepatide

**Canonical HTML:** https://www.kesho.health/glossary/tirzepatide  
**Markdown:** https://www.kesho.health/md/glossary/tirzepatide

## Definition

Tirzepatide activates both GIP and GLP-1 receptors, improving blood sugar control and promoting greater weight loss than GLP-1-only agents in some trials.

## Extended

Weekly injectable tirzepatide costs roughly ₹15,000–₹25,000 monthly in India. Limited generic competition exists. Prescribing follows same Schedule H and safety precautions as other incretin therapies. In India, these concepts appear in RSSDI and ICMR guidance for type 2 diabetes and obesity care—always confirm details with your prescribing physician.

## Learn more

[Full guide](https://www.kesho.health/blog/semaglutide-vs-tirzepatide) · [MD](https://www.kesho.health/md/blog/semaglutide-vs-tirzepatide)

## Related terms

- [semaglutide](https://www.kesho.health/glossary/semaglutide)
- [gip](https://www.kesho.health/glossary/gip)
- [glp-1-receptor-agonist](https://www.kesho.health/glossary/glp-1-receptor-agonist)